How is Stem Cell Treatment for Multiple Sclerosis (MS) done?
At Stem Cell Mexico, stem cell treatment for multiple sclerosis (MS) is a structured, minimally invasive process coordinated with your neurologist's care.

It begins with a review of your neurology records and MRI reports, continues with a phone or video consultation with the doctor, a written plan and an in-person evaluation, and centers on the application of allogeneic mesenchymal stem cells (MSCs) from Wharton's jelly of the umbilical cord. The main route is a slow intravenous (IV) infusion, usually between 100 and 200 million cells; in selected cases, after the doctor reviews your medical reports, an additional intrathecal application (similar to an epidural, usually about 60 million cells) is added. You spend one night, sometimes two, at our facilities with nursing and medical monitoring, and follow-up continues by phone and email. MS plans typically cost $7,000 to $9,500 USD. Your disease-modifying therapy continues, and results vary between patients.
This guide walks through each step, with practical advice for traveling with MS.
Why coordination with your neurologist matters
MS treatment is built on disease-modifying therapies that reduce relapses and slow progression. Regenerative treatment is added to that foundation. Coordination matters for three reasons:
- Timing: some infusion therapies affect the immune system for months, so the doctor plans the MSC application during a stable phase.
- Safety: your neurologist knows your relapse history, MRI activity and other medications.
- Measurement: your neurologist's exams and MRI scans provide an objective record before and after treatment.
A typical itinerary
- Day 1: pickup in the San Diego airport area, border crossing with our driver, laboratory tests and in-person evaluation, followed by the IV infusion and, when indicated, the intrathecal application; night at our facilities.
- Day 2: check-up with the doctor and, if your plan includes a second night, rest and observation; otherwise discharge and return to San Diego.
- Day 3 (when applicable): discharge and return.
Wheelchair-accessible transportation and help with transfers can be arranged in advance, and a companion is welcome to stay nearby during the visit.
Step 1: Records review
You send:
- Neurology notes with your type of MS, disability level (EDSS if available) and date of your last relapse.
- Recent MRI reports of the brain and spinal cord.
- Your disease-modifying therapy and the date of your last dose or infusion.
- Other medications, including those for spasticity, bladder symptoms, pain, mood and sleep.
- Recent blood work, if available.
Step 2: Consultation with the doctor
A complimentary phone or video consultation allows the doctor to understand your symptoms, goals and current treatment, and to explain what MSC therapy can support. Goals are made specific, such as fatigue, walking distance, balance or bladder symptoms, so they can be measured later. The doctor also explains whether you may be a candidate for the intrathecal application, which is decided after reviewing your reports.
Step 3: Written plan and preparation
You receive a written plan by email that lists the number of cells and routes, the nights at our facilities with nursing and medical monitoring, the consultation with your doctor and the stem cell specialist, ground transportation and the total price, with the deposit that reserves your date.
Typical preparation instructions include:
- Continue your disease-modifying therapy as prescribed, with timing coordinated with your neurologist.
- Continue medications for spasticity, bladder symptoms and pain on schedule.
- Pause anti-inflammatory painkillers, alcohol, tobacco and cannabis for about seven days before treatment, and supplements such as omega 3, turmeric and ginger for about five days before, as the doctor indicates.
- Review blood thinners with the doctor; they are never stopped without medical guidance.
- Plan rest before travel and bring cooling items in warm months, such as a fan or cooling vest.
Step 4: Arrival and evaluation
On arrival, you have blood tests and an in-person evaluation, including a neurological examination. The doctor confirms the plan. Treatment is postponed if you have a fever, an infection or signs of an active relapse.
Step 5: The application
The cells
Allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with the mother's informed consent and donor screening. They are prepared in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release. Stem Cell Mexico uses only this cell type.
The IV infusion
- A small catheter is placed in a vein in your arm.
- Baseline vital signs are recorded.
- The cells are infused slowly, usually over 30 to 60 minutes.
- Blood pressure, heart rate, oxygen and temperature are monitored during and after the infusion.
The intrathecal application (selected cases)
- You sit or lie on your side, curled slightly forward.
- The skin of the lower back is cleaned and numbed with local anesthetic.
- A thin needle is placed between two vertebrae into the fluid that surrounds the spinal cord, similar to an epidural or lumbar puncture.
- The cells are injected slowly, and the needle is removed.
- You lie flat for a period afterward, as the doctor indicates, to reduce the chance of headache.
The intrathecal route places cells closer to the brain and spinal cord, where MS lesions occur. Possible effects include temporary headache or back discomfort; infection is rare when sterile technique is used.
Step 6: Observation
You stay at our facilities with nursing and medical monitoring. The team watches for temporary fever, headache or fatigue, the most common reactions after MSC applications. Because heat and fever can temporarily worsen MS symptoms, temperature is monitored closely and treated promptly with paracetamol (acetaminophen) and cooling measures.
Step 7: Discharge and recovery
Before discharge, the doctor reviews how you feel and gives written instructions:
- Rest on the day of treatment and the following day.
- Drink fluids and lie down if you develop a headache after an intrathecal application; contact the team if it is severe or worse when standing.
- A temporary increase in MS symptoms with fever usually resolves when the temperature returns to normal.
- Continue all your medications.
- Seek care for high or persistent fever, new weakness, vision loss, severe headache or signs of infection.
No treatment is free of risk, and these instructions help detect problems early.
Step 8: Follow-up
Our team stays in contact through follow-up calls and messages. Recovery is gradual, and each person responds differently: some patients notice changes in fatigue, balance or mobility within the first weeks, while others notice them over the following months. We recommend recording walking tests, fatigue scores and daily function at three and six months and sharing them with your neurologist, along with your routine MRI. Based on your progress, the doctor may recommend a second application.
What the evidence supports
- Safety: in the MESEMS trial, a phase 2 randomized, double-blind study in The Lancet Neurology, MSC infusions in people with MS were safe and well tolerated. A 2026 meta-analysis of umbilical-cord-derived MSCs in Stem Cells Translational Medicine found temporary fever as the most consistent side effect, without an increase in serious adverse events.
- Immune and protective effects: MSCs release signals that help regulate the immune response and protect nerve tissue, which is the basis for their use as a complement to MS care.
- Different approach from aHSCT: autologous hematopoietic stem cell transplantation, studied in a 2019 JAMA trial, is an intensive hospital procedure with chemotherapy and is different from MSC therapy. The MS International Federation describes the role of each type of stem cell treatment.
Tips for traveling with MS
- Request wheelchair assistance at the airport if you tire easily or use a walking aid.
- Keep water and cooling items at hand, especially in warm months.
- Plan restroom stops and bring any catheter supplies you use.
- Travel with a companion if possible.
- Allow a rest day after returning home, and keep your follow-up appointments with your neurologist.
Who may be a candidate
- Confirmed MS with neurology records and recent MRI reports.
- Stable disease, without a relapse in the recent weeks.
- Continued care with a neurologist.
- No active infection and no cancer within the past five years.
Questions to ask during your evaluation
- How will treatment be coordinated with my disease-modifying therapy?
- Am I a candidate for the intrathecal application?
- How many nights will I stay?
- What should I do if my symptoms worsen with fever?
- How will we measure results?
Bottom line
Stem cell treatment for multiple sclerosis at Stem Cell Mexico follows a coordinated process: records review, consultation, written plan, evaluation, IV infusion of Wharton's jelly MSCs and, in selected cases, an intrathecal application, followed by observation and follow-up shared with your neurologist. Your disease-modifying therapy continues, and results vary between patients. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your type of MS, goals and medical history.
References
- MS International Federation (MSIF): Stem cell therapy for MS (opens in a new tab)
- Uccelli A et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. The Lancet Neurology, 2021 (opens in a new tab)
- Burt RK et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA, 2019 (opens in a new tab)
- Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
